Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey.
David Clemow, Christine Radawski, Joe Milata, Karla Alaka, Theresa Hunter Gibble, Adam Schaum, Obi Ezennia, Nicholas Martinez, Tibor Szaloki, Yuka Ito, Danielle Rodriguez, Katherine Kirk
{"title":"Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey.","authors":"David Clemow, Christine Radawski, Joe Milata, Karla Alaka, Theresa Hunter Gibble, Adam Schaum, Obi Ezennia, Nicholas Martinez, Tibor Szaloki, Yuka Ito, Danielle Rodriguez, Katherine Kirk","doi":"10.1093/crocol/otae054","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is a need to better understand ulcerative colitis (UC) patient and healthcare provider (HCP) treatment satisfaction, acceptability, and preferences.</p><p><strong>Methods: </strong>Two international, cross-sectional, web-based surveys were conducted among participants of a phase 3 mirikizumab study (NCT03519945). The questions captured moderate-to-severe UC patients' experience, HCPs' perception of patients' experience, and HCPs' own experience with mirikizumab administration through intravenous (IV) infusions and subcutaneous (SC) injections.</p><p><strong>Results: </strong>Respondents included 93 patients and 42 HCPs from 11 countries. The majority of patients had UC >4 years (74.2%), were bionaive (68%), in remission at the time of the survey (63%). HCPs were primarily from the United States (57%), generally nurses (41%) or gastroenterologists (26%) with ≥6 years of experience in treating UC (57%). Most patients were \"very satisfied/satisfied\" (IV, 83%; SC, 91%), \"completely/somewhat\" accepting of mirikizumab administration (IV, 87%; SC, 97%), and agreed that improvement to their UC outweighed any administration dissatisfaction (90%). HCPs' perspectives of patients' experiences were higher: \"very satisfied/satisfied\" (IV, 93%; SC, 100%); \"completely/somewhat\" accepting (IV, 90%; SC, 98%). HCPs themselves were \"very satisfied/satisfied\" (IV, 81%; SC, 95%); gastroenterologists were \"very satisfied\" (IV, 82%; SC, 82%) more than nurses (IV, 29%; SC, 65%) who were generally at least \"satisfied\" (IV, 53%; SC, 35%). Two SC and monthly SC injections were \"completely acceptable\" by the patients (76% and 85%) and per HCPs' perceptions of patients' preferences (69% and 100%).</p><p><strong>Conclusions: </strong>Both patients and HCPs were satisfied with and accepted mirikizumab IV induction followed by monthly maintenance SC injections. UC improvement outweighed any administration dissatisfaction.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"6 4","pages":"otae054"},"PeriodicalIF":1.8000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520749/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Crohn's & Colitis 360","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/crocol/otae054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: There is a need to better understand ulcerative colitis (UC) patient and healthcare provider (HCP) treatment satisfaction, acceptability, and preferences.
Methods: Two international, cross-sectional, web-based surveys were conducted among participants of a phase 3 mirikizumab study (NCT03519945). The questions captured moderate-to-severe UC patients' experience, HCPs' perception of patients' experience, and HCPs' own experience with mirikizumab administration through intravenous (IV) infusions and subcutaneous (SC) injections.
Results: Respondents included 93 patients and 42 HCPs from 11 countries. The majority of patients had UC >4 years (74.2%), were bionaive (68%), in remission at the time of the survey (63%). HCPs were primarily from the United States (57%), generally nurses (41%) or gastroenterologists (26%) with ≥6 years of experience in treating UC (57%). Most patients were "very satisfied/satisfied" (IV, 83%; SC, 91%), "completely/somewhat" accepting of mirikizumab administration (IV, 87%; SC, 97%), and agreed that improvement to their UC outweighed any administration dissatisfaction (90%). HCPs' perspectives of patients' experiences were higher: "very satisfied/satisfied" (IV, 93%; SC, 100%); "completely/somewhat" accepting (IV, 90%; SC, 98%). HCPs themselves were "very satisfied/satisfied" (IV, 81%; SC, 95%); gastroenterologists were "very satisfied" (IV, 82%; SC, 82%) more than nurses (IV, 29%; SC, 65%) who were generally at least "satisfied" (IV, 53%; SC, 35%). Two SC and monthly SC injections were "completely acceptable" by the patients (76% and 85%) and per HCPs' perceptions of patients' preferences (69% and 100%).
Conclusions: Both patients and HCPs were satisfied with and accepted mirikizumab IV induction followed by monthly maintenance SC injections. UC improvement outweighed any administration dissatisfaction.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
